Technological Advancements in Energy-Based Aesthetic Devices Boost Its Market

Key factors such as the growing adoption of non-invasive procedures, growth in aging population, increasing awareness among customers, technological advancements in energy-based medical aesthetics devices, and increasing demand for aesthetic treatments among the male population are driving the growth of the aesthetic devices market. However, stringent safety regulations for aesthetic procedures, social stigma associated with cosmetic treatments, and low focus of market players on developing medical aesthetic devices for dermatological conditions are restraining the growth of this market.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=885

Medical aesthetics devices are used to improve the cosmetic appearance through the treatment of conditions such as liver spots, excess fat, scars, skin laxity, wrinkles, moles, cellulite, unwanted hair, spider veins, and skin discoloration.

Allergan, Inc. (Ireland), Cynosure, Inc. (U.S.), Lumenis Ltd. (Israel), Mentor Worldwide LLC (U.S.), PhotoMedex, Inc. (U.S.), Galderma S.A. (Switzerland), Solta Medical, Inc. (U.S), Syneron Medical, Ltd. (Israel), and ZELTIQ Aesthetics, Inc. (U.S.) are some of the key players in the global medical aesthetics market.

In 2016, North America is expected to account for the largest share of the global medical aesthetics market, followed by Europe. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period, owning to key factors such as rising consumer awareness and interest in aesthetic procedures, aggressive marketing by leading U.S. and European companies, and rising medical tourism in the region. Over the past three years, a number of market players, including Cynosure, Inc. (U.S.), Syneron Medical Ltd. (Israel), Allergan, Inc. (U.S.), and Galderma S.A. (Switzerland) have strategically expanded their presence in emerging Asia-Pacific countries to leverage the high growth potential in the region.

Related Article : http://prsync.com/marketsandmarkets/marketsandmarkets-medical-aesthetics-market-worth--million-by--1041643/

Venipuncture needle and syringes market is projected to reach USD 1,044.6 Million by 2021 from USD 790.8 Million in 2016

Venipuncture is the procedure of collecting blood from veins through venous access. Intravenous cannulation access is the method to get venous access for venipuncture. Distal to the antecubital fossa in deep-arm veins allows most successful cannulation. Moreover, medical condition of the patient and the experience and training of the technician performing the peripheral intravenous (PIV) access increases the success rate of PIV. Alternate approaches to attain cannulation include central venous catheterization (CVC), peripherally inserted central catheters, external jugular IVs, and ultrasound-guided vascular access.

For More Information : http://www.marketsandmarkets.com/speaktoanalyst.asp?id=105976374

Venipuncture needle and syringes market is projected to reach USD 1,044.6 Million by 2021 from USD 790.8 Million in 2016, at a CAGR of 5.7% during the forecast period. The U.S. total venipuncture procedure volume contributed the largest share in 2016 and poised to grow at a CAGR of 1.8%.

Factors such as aging population, cardiovascular disease death rate, pediatric population, chronic diseases conditions will make venipuncture difficult. It becomes difficult for patients with chronic diseases like diabetes, cancer, and cardiovascular conditions; thus, the increasing incidence of these diseases will increase the overall difficulty of the procedure. The lack of skilled professionals will also make venipuncture becomes difficult to perform.

Based on vein type, the venipuncture procedures of Canada are classified into median cubital vein, cephalic vein, basilic vein, and other veins. The other veins segment includes great saphenous, femoral, scalp, subclavian, and metacarpal veins. The procedures in each vein type are further divided into total venipuncture procedures and successful venipuncture procedures. In 2016, the median cubital vein segment is expected to account for the largest share of the venipuncture procedures.

Related Article : https://www.marketwatch.com/story/venipuncture-needle-and-syringes-market-worth-10446-million-usd-by-2021-2017-03-15-62033115

The western blotting market was USD 574.8 Million in 2016, Expecte High Growth

Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.S.), Advansta, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Cell Signaling Technology, Inc. (U.S.) are some of the key players in the market worldwide.

For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=235810711

On the basis of region, this market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. The U.S. is the largest market in North America, owing to the increasing prevalence of HIV and Lyme disease, U.S.- China collaborative program for biomedical research, rise in research funding and increasing production of genetically modified crops, and rising number of conferences. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.  This can be attributed to the increasing government interest in biomedical & biotechnology industry in China, presence of bioclusters in China and India, government initiatives supported by funding in Japan, growing pharmaceutical industry in India backed by government initiatives, Korea-U.S. Free Trade Agreement (KORUS), and growing prevalence of HSV in south east Asia.

The western blotting market is expected to be dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is expected to grow at the highest rate during the forecast period.

The western blotting market is expected to reach USD 730.7 Million in 2021 from USD 574.8 Million in 2016, growing at a CAGR of 4.9%. Increasing number of research activities and R&D spending by pharmaceutical and biotechnology companies, rising prevalence of HIV/AIDS, growing proteomics market, growing number of industry-academic research collaborations, increasing demand for personalized medicine, and new product launches are expected to drive the growth of the market in the coming years.

The biologics safety testing market was valued at USD 2.75 Billion in 2017

The top four players in this market are Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany) and SGS SA (Switzerland) are. These companies have a broad product & service portfolio with comprehensive features and have a strong geographical presence.

By region, the global biologics safety testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016 followed by Europe, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.

For More Informartion : http://www.marketsandmarkets.com/pdfdownload.asp?id=34624144

Biologics safety testing is a mandatory process in pharmaceutical and biotechnological companies. It is used as a quality control measure for the drug development process. The biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% from 2017 to 2022. Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.

On the basis of products and services, the global market is segmented into kits & reagents, services, and instruments. The kits & reagents segment accounted for the largest share of the products segment. This growth can be attributed to the regular and repeated purchase of kits & reagents as compared to instruments.

On the basis of applications, the global market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing, and stem cell research.The vaccine and therapeutics development segment holds the largest share in the market. The growth of this segment is primarily attributed to the increase in initiatives for immunization, increase company investment in vaccines development and the rising prevalence of diseases.

The global high-content screening market estimated USD 557.1 Million in 2017

The major players in the market are GE Healthcare (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Becton, Dickinson and Company (U.S.). Some of the other leading players in this market include BioTek Instruments Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Tecan Group Ltd. (Switzerland), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).

For More Informartion: http://www.marketsandmarkets.com/pdfdownload.asp?id=42710391

North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major lifesciences market players, and government support are some of the factors attributed to the large share of North America in the HCS market.

The global high-content screening market is projected to reach USD 909.0 Million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are growth in funding for cellular research, cost containment in pharma R&D, and technological advancements in HCS solutions. The rapid growth in developing countries across APAC is also expected to provide an opportunity for revenue generation in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of the instruments are expected to restrain the market growth.

Based on application, the market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation. In 2016, the primary & secondary screening segment dominated the market. The dominant share of this segment is attributed to its wide usage in qualitative assays to exclude the compounds with unintended modes of action, evaluation of bioavailability and lead specificity.

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and contract research organizations. In 2016, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global high-content screening market. The large share of this segment is attributed to the wide usage of HCS in preclinical and clinical studies in the pharmaceutical and biotechnology industries.

The global needle-free injection system market in terms of value USD 9.81 Billion in 2016

Key players in the needle-free injection system market include  Antares Pharma, Inc. (U.S.), Endo International plc (U.S.), PharmaJet (U.S), Bioject Medical Technologies Inc. (U.S), Medical International Technology, Inc. (U.S), INJEX Pharma AG (Germany), National Medical Products Inc. (U.S.), Valeritas, Inc. (U.S.), European Pharma Group (Netherland), PenJet Corporation (U.S), Crossject SA (France).

For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=165815861

The market is dominated by North America, followed by Europe, Asia, and the Rest of the World. While North America is expected to dominate the market in 2016, Europe is expected to grow at the highest CAGR during the forecast period.  The high growth in this market is attributed to the rising demand for biologics, growing prevalence of chronic diseases, technological advancements, mergers and acquisitions by major companies in the market, favorable reimbursement policies, increasing healthcare expenditure and regulatory approvals of new injection system are key factors driving the market growth in Europe

The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 Billion by 2021 from USD 9.81 Billion in 2016, at a CAGR of 15.5% during the forecast period. Growth in this market is mainly driven by growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, rising demand for biosimilars and vaccination, advantages of drug delivery technology, increasing demand for self-injection devices. On the other hand, high development cost of needle-free injection systems over the conventional needle injection may hinder the growth of this market during the forecast period.

Based on the technology, the market is divided into Jet-based needle-free injectors, spring-based needle-free injectors, laser-based needle-free injectors and vibration-based needle-free injectors. The jet-based needle-free injector is expected to account for the largest market share in 2016, due to their advantages over the other injector systems.

Based on the Applications, the market is segmented into vaccine delivery, insulin delivery, Oncology, pain management and other applications; the vaccine delivery application segment is projected to be the fastest-growing segment during forecast period in 2016. The growth of this market primarily attributed to factors such as the rising incidence of chronic diseases, technological advancement, and growing preference for self-medication.

The global medical device reprocessing market USD 823.5 Million in 2017, Projected High Growth

Geographically, the global medical device reprocessing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America dominated the market, and this is primarily attributed to its well-established healthcare industry, growing prevalence of chronic diseases, and increasing volume of surgical procedures. The European region is expected to witness the highest CAGR during the forecast period, owing to the rising prevalence of chronic diseases, increasing geriatric population, rising healthcare expenditure, increasing number of surgical procedures, and growing awareness about the usage of reprocessed medical devices

For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=583

The global medical device reprocessing market is projected to reach USD 1,754.0 Million by 2022 from USD 823.5 Million in 2017, at a CAGR of 16.3%. The growth of this market is majorly driven by the increased utilization of the low priced reprocessed medical devices as compared to new devices, increased efforts towards reducing regulated medical waste (RMW), and rising number of surgical procedures associated with the growing prevalence of chronic diseases. However, the risk of transmission of surgical site infections associated with the use of reprocessed devices may hinder the growth of the market to a certain extent.

In 2016, Stryker Corporation (U.S.) and Johnson & Johnson (U.S.) dominated the global medical device reprocessing market. Some of the other players competing in this market are Vanguard AG (Germany), Medline ReNewal (U.S.), Medtronic plc (Ireland), SteriPro Canada, Inc. (Canada), Pioneer Medical Devices AG (Germany), Vascular Solutions, Inc. (U.S.), HYGIA Health Services, Inc. (U.S.), ReNu Medical, Inc. (U.S.), SureTek Medical (U.S.), and Centurion Medical Products Corporation (U.S.).

The reprocessing practices are regulated by various regional regulatory authorities. The changing regulatory scenario favoring medical device reprocessing in a number of countries, such as France and Japan, will open up new areas of opportunity for market players. For example, till 2016, the outsourcing of medical device reprocessing was prohibited in France; however, the European Union (EU) Regulations (Article 17), released on April 5, 2017, mandated the use of third-party reprocessing services by all French hospitals. These regulations are expected to be implemented in France by 2020. Similarly, Japan does not currently have any regulations for the reprocessing of single-use medical devices. Therefore, regulatory authorities, such as the Ministry of Health, Labor and Welfare (MHLW) (Japan), in collaboration with the FDA (U.S.), are focusing on generating new medical device reprocessing guidelines for Japan.

The global HLA typing for transplant market USD 535.0 Million in 2016,America and Europe to be the mature markets

In 2016, North America and Europe are expected to be the mature markets for HLA typing products for transplant. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the HLA typing for transplant market in the next five years. The North America is expected to hold the largest share of the global HLA typing for transplant market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of HLA-based transplant diagnostics.

For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=96374742

Europe is expected to hold the second-largest share of the global HLA typing for transplant market in 2016. This leading market position of the European market is due to factors such as rising acceptance of genome-based diagnostic techniques by healthcare professionals, large number of organ transplantation procedures performed annually, presence of a large number of biotechnology and molecular diagnostic companies, and rapid growth in the aging population.

Thermo Fisher Scientific, Inc. (U.S.) dominated the global HLA typing for transplant market with a share of 42.0% in 2015. In the past three years, the company adopted strategic acquisitions and geographic expansions as key growth strategies to maintain its dominant position in the global transplant diagnostics market. Other leading players present in the HLA typing for transplant market are Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.

The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, at a CAGR of 7.1% from 2016 to 2021.

The medical connectors market was USD 1.63 Billion in 2016,Dominated by North America

Geographically, the market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by the increase in the prevalence and incidence of chronic diseases and increased demand for better healthcare infrastructure. The major players in the market are Amphenol Corporation (U.S.), Delphi Automotive LLP. (U.K.), Esterline Corporation (U.S.), ITT Corporation (U.S.), Smiths Interconnect (U.K.), TE Connectivity Ltd. (Switzerland), Fisher Connectors (Switzerland), Lemo S.A. (Switzerland), Molex (U.S.), and Samtec (U.S.).

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=81731061

The medical connectors market is projected to reach USD 2.69 Billion by 2021 from USD 1.63 Billion in 2016, at a CAGR of 10.5%. The high incidence and prevalence of chronic disorders, rise in healthcare expenditure, and growth in the home healthcare market are the major factors fueling the growth of this market.

Key players in the market include Amphenol Corporation (U.S.), Delphi Automotive LLP. (U.K.), Esterline Corporation (U.S.), ITT Corporation (U.S.), Smiths Interconnect (U.K.), TE Connectivity Ltd. (Switzerland), Fisher Connectors (Switzerland), Lemo S.A. (Switzerland), Molex (U.S.), and Samtec (U.S.).

The pharmaceutical robots market was USD 64.4 Million in 2016 , projected High Growth coming years

The traditional robots segment is further categorized into articulated, SCARA (selective compliance articulated robot arm), delta/parallel, Cartesian, and other robots (which include spherical and dual-arm robots). The articulated robots segment accounted for the largest share of the global pharmaceutical traditional robots market in 2016. Articulated robots are easier to align to multiple planes, simple to operate and maintain, and have a greater work envelope. Moreover, these robots provide a wide variety of payload capacities. These factors contribute to the high share of this segment.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=210985096

Kawasaki Heavy Industries Ltd. (Japan), FANUC Corporation (Japan), KUKA AG (Germany), Mitsubishi Electric Corporation (Japan), ABB Ltd. (Switzerland), Denso Corporation (Japan), Seiko Epson Corporation (Japan), Marchesini Group S.p.A (Italy), Universal Robots A/S (Denmark), Yaskawa Electric Corporation (Japan), and Shibuya Corporation (Japan) are some of the key players in the pharmaceutical robots market.

In 2016, Asia-Pacific accounted for the largest share of the global pharmaceutical robots market, followed by Europe, North America, and RoW. During the forecast period, Asia-Pacific is also expected to witness the highest growth. The large share and high growth of Asia-Pacific can be attributed to the increase in domestic industrial robot companies, flourishing pharmaceutical industry, increasing number of conferences and exhibitions, investment and funding in the industrial robots industry, and Japan’s Robot Strategy.

Radiation Dose Management Market: Geographic Growth Opportunities

The key players in the radiation dose management market are Bayer AG (Germany), GE Healthcare (U.S.), PACSHealth LLC (U.S.), Philips Healthcare (Netherlands), Fujifilm Holdings Corporation (Japan), Novarad Corporation (U.S.), Siemens Healthineers (Germany), AGFA Healthcare (Belgium), Sectra AB (Sweden), QAELUM N.V. (Belgium), Bracco Imaging S.p.A. (Italy), and Medsquare (France). Key players in the radiation dose management market are pursuing several organic and inorganic growth strategies such as product launches & upgrades, partnerships, collaborations & agreements, acquisitions, and expansions to garner larger shares in the market.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=82326344

The market in Europe is expected to grow at the highest CAGR during the forecast period. Government initiatives in this region to increase patient safety and the need to improve overall efficiency in healthcare organizations are driving the growth of the European market. The EU directives regarding the use of ionizing radiation, which will be repealed from February 6, 2018, is a prime factor for the increasing adoption of radiation dose management solutions by healthcare providers in Europe, which in turn is driving the growth of this geographic segment during the next two years

The global radiation dose management market is estimated to grow at a CAGR of 42.0% from 2017 to 2022, to reach USD 931.3 Million by 2022 from USD 161.3 Million in 2017. This market is mainly driven by the increasing needs to cut radiation dose levels causing chronic diseases, need for regulatory compliance, and need for improved patient safety and for accurate and reliable systems to manage critical radiation dose levels and information. Moreover, the safe and ensured environment through radiation dose management systems results in a streamlined workflow, thus increasing the operational efficiency and quality of healthcare organizations. However, lack of funding and lack of standardized protocols for radiation dose management are expected to restrain the growth of this market to a certain extent in the developing regions.

Anatomic Pathology Market ,North America: Market Size, By Product & Service (USD Million)

Key players operating in the anatomic pathology market include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Sakura Finetechnical Co., Ltd. (Japan), Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), and NeoGenomics Laboratories, Inc. (U.S.)

The anatomic pathology market is expected to reach USD 21.9 Billion by 2021 from USD 16.2 Billion in 2016, at a CAGR of 6.1%.

Based on region, the global market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, the Asian region is expected to witness the highest growth during the forecast period. The presence of emerging economies like China, India, and Japan; the large population and rising prevalence of chronic diseases in these countries; improving standards of living; growing demand for quality medical care; increasing healthcare spending and government initiatives; rising awareness about the use of anatomic pathology tests among physicians; and growth in the demand for diagnostics are some major factors driving the high growth of this regional segment.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=137323145

The global anatomic pathology market is segmented on the basis of product & service and application. Anatomic pathology involves the diagnosis of various types of cancer, infectious diseases, and medical conditions through the examination of cells and tissue samples, which are collected from patients through biopsy. The market is witnessing high growth due to factors such as increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure.

Laboratory Freezers Market: Emerging vs. Developed Markets

The major players in the global laboratory freezers market are Thermo Fisher Scientific Inc. (U.S.), Haier Biomedical (China), Eppendorf AG (Germany), Helmer Scientific (U.S.), VWR Corporation (U.S.), ARCTIKO A/S (Europe), Biomedical Solutions Inc. (U.S.), EVERmed S.R.L. (Italy), Philipp Kirsch GmbH (Germany), and Panasonic Healthcare Co., Ltd. (Japan).

The global laboratory freezers market is studied at regional and country levels. In 2015, North America represented the largest regional market, followed by Europe. Although North America will continue to dominate the global market during the forecast period, the Asia-Pacific region is expected to register the highest market growth in the coming years. A majority of the growth in this region is driven by the improving healthcare infrastructure, increasing investments by government agencies, growth in biotechnology research, and rising focus of key market players on emerging Asia-Pacific countries.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=196600540

The global laboratory freezers market is estimated to reach USD 3.76 Billion by 2021, at a CAGR of 4.6% during the forecast period. The increasing demand for blood & blood components and growing number of organ transplant procedures are the key factors driving the growth of the global market. However, the availability of low-cost products from a large number of local players and increasing use of refurbished equipment are some of the major factors restraining the growth of this market.

The laboratory freezers market is segmented by product type, end user, and region. This research report discusses the key market drivers, restraints, opportunities, and challenges in the global market and its submarkets. Based on product type, the market is segmented into freezers, refrigerators, and cryopreservation systems. The freezers segment accounted for the largest share of the market in 2015, and is expected to grow at a significant CAGR during the forecast period. Technological advancements in freezers and increasing use of plasma freezers as a result of the growing demand for plasma from biopharmaceutical companies are driving the growth of this market segment.

PCR to Dominate the Molecular Diagnostic Technologies Market

The study also provides analytical framework to understand various factors that determine the purchase decision of PCR instruments by end users. These factors include sensitivity, consistent quality of data, high-throughput ability, multiplexing capability, price of instrument, ease of use, services and support, and brand of a system, among others. The purchase decision of PCR instrument is based on these parameters, and their importance differs as per the diagnostics requirements of various end users.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=249309546

The study analyses various pricing components of PCR systems. Pricing of PCR system can be broken down into several components which include machine cost, training cost, service and software cost, and maintenance cost, among others.

The overall market for PCR technology is expected to grow rapidly as the expansion of its application areas and increased accuracy and precision. Furthermore, specific technology segments of the PCR market, such as dPCR (digital PCR) and qPCR (real-time PCR), are witnessing higher market growth owing to their benefits such as real-time process monitoring, low reagent consumption, automation of workflow, and greater reproducibility and precision. The real-time PCR segment commanded the largest share of the global PCR market in 2014, due to the several factors including technological advancements, increasing use of qPCR in research and medical diagnostics, growing use of robotics for lab automation, and expansion of installation base.

PCR is a well-adopted molecular diagnostics technique, and has a wide range of applications ranging from diagnosis of infectious disease, cancer, personalized medicine, and identification of target therapies for particular disease condition. This report provides qualitative assessment of the PCR technology in terms of pricing, replacement trends, competitors’ portfolio analysis, and selection criteria for adoption of PCR instruments from an end-user perspective.

Varicose Vein Treatment Market in North America and Europe worth 289.7 Million USD by 2021

The report "Varicose Vein Treatment Market in North America and Europe by Treatment Mode (Endovenous Ablation, Sclerotherapy, Stripping), Products (Laser & RF Ablation, Venous Closure, Surgical) - Forecasts to 2021", The varicose vein treatment market in North America and Europe is expected to reach USD 289.7 Million by 2021 from USD 207.9 Million in 2016, at a CAGR of 6.9% between 2016 and 2021.

The report provides a detailed overview of the major drivers, restraints, opportunities, and challenges impacting the varicose vein treatment market in North America and Europe along with the estimates and forecasts of the revenue and market share analysis.

The varicose vein treatment market is poised to witness a steady growth between 2016 and 2021. Shift towards less-invasive treatment procedures, availability of advanced varicose vein treatment devices, huge burden of varicose vein cases in North America and Europe, improving patient compliance & reliability, growing healthcare expenditure, and rapid growth in aging population will majorly drive the varicose vein treatment market.

Download PDF brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=22524107

This report broadly segments the varicose vein treatment market into mode of treatment and products. The varicose vein treatment market, by products is segmented into ablation devices, venous closure products, and surgical products. The ablation devices segment is further categorized into radiofrequency ablation devices and laser ablation devices. On the basis of mode of treatment, the varicose vein treatment market is segmented into endovenous ablation, injection sclerotherapy, and surgical ligation/stripping.

This report covers the varicose vein treatment market across two major geographies, namely, North America and Europe. In this report, the North American varicose vein treatment market is further segmented into the U.S. and Canada, while the European varicose vein treatment market is categorized into Germany, U.K., France, Italy, Spain, and Rest of Europe. In 2016, North America is expected to command the largest share of the varicose vein treatment market in North America and Europe. However, Europe is expected to register the highest growth rate during the forecast period from 2016 to 2021, due to increasing adoption of advanced treatment procedures and favorable government initiatives in this region.

Medtronic plc (Ireland); AngioDynamics, Inc. (U.S.); biolitec AG (Austria); Syneron Medical Ltd. (Israel); Lumenis Ltd. (Israel); Dornier MedTech GmbH (Germany); Energist Group (U.K.); Eufoton s.r.l. (Italy); Vascular Solutions, Inc. (U.S.); Quanta System S.p.A. (Italy); Sciton, Inc. (U.S.); Fotona d.o.o. (Slovenia); BTG plc (U.K.); and Merz Aesthetics (U.S.) are the key players in the varicose vein treatment market.

IV Equipment Market worth 13.63 Billion USD by 2022

The global IV equipment market is projected to reach USD 13.63 Billion by 2022, at a CAGR of 6.2% from 2017 to 2022. 

The market growth can be attributed to a number of factors such as increasing incidence of chronic diseases, rising geriatric population, growing number of surgical procedures performed, rising number of needlestick injuries, and rising demand for ambulatory infusion pumps.

In this report, the global IV equipment market is segmented on the basis of product, end user, and region. Based on product, the market is segmented into IV catheters, administration sets, infusion pumps, securement devices, stopcocks & check valves, drip chambers, needleless connectors, and other IV equipment (luer adapters, cannula, capping systems, spikes, needles, clamping systems, and IV stands). In 2016, IV catheters accounted for the largest share of the global IV equipment market. The increasing prevalence of chronic diseases and the growing number of surgical procedures contributes to their largest share in the market.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=78345313

On the basis of end user, the market is classified into hospitals & clinics, home care, and ambulatory care centers. In 2016, the hospitals segment accounted for the largest share of the market. This can largely be attributed to the strong financial capabilities of hospitals for purchasing high-priced IV devices as well as the availability of trained professionals to operate them.

In 2016, North America accounted for the largest share of the global IV equipment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa. This large share of the North American region can be attributed to the rising geriatric population, increasing prevalence of chronic diseases, the presence of a well-established healthcare industry, growing demand for advanced medical treatments, the presence of major players, and increasing government healthcare expenditure.

The Asia-Pacific region is expected to witness the highest growth in the forecast period. Factors such as the presence of a large patient pool, rising geriatric population, growing utilization of technologically advanced IV products, increasing focus on home healthcare, growing healthcare expenditure, rapidly developing healthcare infrastructure, and increasing per capita income are driving the growth of the IV equipment market in the Asia-Pacific region.

Patient safety risks and medication errors associated with infusion pumps leading to product recalls are expected to hinder the growth of this market.

The major players in the IV equipment market are Becton, Dickinson and Company (U.S.), B. Braun Melsungen AG (Germany), Baxter International Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), ICU Medical, Inc. (U.S.), Smiths Medical (U.K.), Moog, Inc. (U.S.), Terumo Corporation (Japan.), C. R. Bard, Inc. (U.S.), and AngioDynamics, Inc. (U.S.).

Healthcare IT Consulting Market in USA

The global HCIT consulting services market is expected to reach USD 45.42 Billion by 2022 from USD 18.38 Billion in 2017, at a CAGR of 19.8%.

A number of factors such as growing digitization in healthcare, rapidly changing HCIT landscape, government support for healthcare IT solutions, growing HCIT expenditure, lack of skilled IT professionals in the healthcare industry, growing venture capital investments in health IT, and the need for data security are driving the growth of this market. On the other hand, end-user concerns regarding the confidentiality are restraining the growth of this market.

The global HCIT consulting services market into type, end user, and region. On the basis of type, the global HCIT consulting services market is segmented into HCIT strategy and project/program management; healthcare application analysis, design, and development; HCIT integration and migration; change management; healthcare/medical system & security set-up and risk assessment; healthcare enterprise reporting and data analytics services; production go-live/post go-live support; healthcare business process management; regulatory compliance; and other consulting services. The healthcare application analysis, design, and development segment is expected to register the highest CAGR during the forecast period. The large share of this segment can be attributed to the fact that IT application analysis, design, and development form the major component of all IT solution implementation projects. Additionally, every healthcare facility has different requirements which need careful designing, development, and implementation of customized solutions.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=42622745

The global HCIT consulting services market, by end user is segmented into healthcare providers, payers, and other end users. In 2017, the healthcare providers segment is expected to account for the largest share of the market. The large share of this segment can primarily be attributed to factors like the rising healthcare costs, growing adoption of HCIT solutions by providers as a means to bring down costs, growing adoption of electronic medical records (EMRs) to improve patient care, increasing hospital consolidation, changing and increasing stringency of regulations for HCIT provider solutions, and growing adoption of HCIT solutions by ACCs, home healthcare centers, and diagnostic centers.

Geographically, the HCIT consulting services market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2017, North America is expected to dominate the market, followed by Europe. The large share of the North American market is attributed to the factors such as government initiatives to enhance adoption of HCIT solutions, increasing government expenditure on HCIT, changing and stringent legislative requirements and accreditations necessary for healthcare IT solutions, and the presence of a large number of IT solutions and services companies in the region.

Some prominent players in the HCIT consulting services market are Accenture plc (Ireland), Cognizant Technology Solutions Corporation (U.S.), Deloitte Touche Tohmatsu Limited (U.S.), Cerner Corporation (U.S.), Siemens Healthineers (Germany), McKesson Corporation (U.S.), Epic Systems Corporation (U.S.), IBM Corporation (U.S.), General Electric Company (U.S.), Tata Consultancy Services Limited (India), Koninklijke Philips N.V. (Netherlands), NTT DATA Corporation (Japan), Infor Inc. (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), and Oracle Corporation (U.S.).

These companies are focusing on strategies such as product launches, expansions, agreements, collaborations, and acquisitions to increase their offerings in the market and cater to the increasing demand for HCIT consulting services.

Related Article :

http://www.24pressrelease.com/11225/news/growing-digitization-in-healthcare-boost-healthcare-it-consulting-market

https://www.wesrch.com/medical/paper-details/press-paper-ME1MS1000YRTG-changes-in-the-hcit-landscape-boost-healthcare-it-consulting-market

Patient Engagement Solutions Market in North America

The patient engagement solutions market is projected to reach USD 16.39 Billion by 2020 from USD 6.68 Billion in 2015, growing at a CAGR of 19.7%. North America is expected to account for the largest share of the market in 2015, followed by Europe, Asia, and the Rest of the World (RoW). However, the European region is expected to grow at the highest CAGR during the forecast period.

The global patient engagement solutions market is segmented on the basis of component, delivery mode, end user, application, and therapeutic area. On the basis of component, the market is segmented into hardware, software, and services. The software segment is estimated to account for the largest share of the global market in 2015. However, the services segment is expected to witness the highest growth rate during the forecast period, owing to the indispensable nature of services which include consulting, storage, and implementation of solutions, training, maintenance, and regular upgrades.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=105975994

Patient engagement solutions find major applications in the health management of a patient. These solutions are also used in social and behavioral management, home health management, and financial management. The health management segment is the fastest-growing segment and is expected to command the largest share of the global market in 2015. Providers are encouraging patients to adopt health management solutions as they help save time for providers as well as increase patient compliance with therapy. Health management solutions empower patients to improve the quality of care, resulting in better outcomes with fast recovery.

Factors such as legislations and initiatives to promote ‘patient-centeredness’ in healthcare, increasing number of accountable care organizations, impetus on fulfilling the requirements of Meaningful Use through patient engagement, growth of the HCIT market, consolidation of healthcare providers, and growing focus on eHealth are driving the growth of the market. However, reluctance among providers towards the adoption of patient engagement solutions, requirement of infrastructural investments, and lack of interoperability are expected to restrain market growth. On the other hand, emerging economies in the Asian region, growing medical tourism, and growing use of cloud-based models offer growth opportunities for players in the market.

Geographically, the patient engagement solutions market is categorized into North America, Europe, Asia, and the Rest of the World (RoW).

Source: Center for Patient and Consumer Engagement, Society for Participatory Medicine, Association for Patient Experience, Institute of Patient and Family Centered Care, Patient Engagement Advisory Committee, American Association of Healthcare Administrative Management (AAHAM), Institute for Health Technology Transformation (iHT2), The Health Foundation, Healthcare Information and Management Systems Society (HIMSS), American Medical Group Association (AMGA), Agency for Healthcare Research and Quality (AHRQ), Health Research & Educational Trust (HRET), American Hospital Association (AHA), International Association of Health Policy (IAHP), Institute of Population and Public Health (IPPH), Public Health Agency of Canada, WHO, OECD, Expert Interviews, and MarketsandMarkets Analysis

McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Phytel, Inc. (U.S.), athenahealth, Inc. (U.S.), Orion Health Ltd. (New Zealand), Cerner Corporation (U.S.), GetWellNetwork, Inc. (U.S.), Lincor Solutions Ltd. (U.S.), YourCareUniverse, Inc. (U.S.), WelVU, Inc. (U.S.), Get Real Health (U.S.), Oneview Healthcare (U.S.), PatientPoint (U.S.), and Medecision, Inc. (U.S.) are the key players in the global patient engagement solutions market.

Polymerase Chain Reaction - Comparative Analysis and End User Preference Study

The overall market for PCR technology market is expected to grow rapidly owing to the expansion of its application areas and increased accuracy and precision. Furthermore, specific technology segments of the PCR market, such as dPCR (real-time PCR) and qPCR (digital PCR), are witnessing higher market growth owing to their benefits such as real-time process monitoring, low reagent consumption, automation of workflow, and greater reproducibility and precision. The real-time PCR segment commanded the largest share of the global PCR market in 2014, due to several factors including technological advancements, increasing use of qPCR in research and medical diagnostics, growing use of robotics for lab automation, and expansion of installation base.

The growing geriatric population, coupled with an increasing prevalence e of chronic diseases, and technological advancements in the field of life science are the key factors driving the growth of qPCR and dPCR market. The rising incidence of infectious diseases and genetic disorders and increased public-private investments, funds, and grants for PCR-based research are further assisting the market growth.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=249309546

However, the high cost of dPCR instruments and technological limitations associated with qPCR and dPCR are the key factors limiting the growth of this market. In addition, the implementation of the Minimum Information for the Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines is a key challenge faced by industry players in this market.

The study provides granular information regarding pricing of PCR instruments with breakdown into various cost components. These cost components include machine cost, accessories cost, training cost, services and software cost, and maintenance cost, among others. The report also provides insights on replacement trends and end-user preferences for PCR systems.

The report also contains detailed analysis of end users of PCR instruments and their preferences. The PCR instruments end-user market can be divided into four distinct segments, reference laboratories, research laboratories/academic institutes/hospitals, medium-sized laboratories, and others (clinical research organizations and forensic laboratories). Reference laboratories commanded the largest share of PCR instrument market owing to increased test volume of infectious diseases and various types of cancers.

The research findings cited in the report encapsulates the important selection criteria for PCR machines from an end-user point of view. It analyses each end-user segment and importance given to the particular criteria while selecting a PCR machine. Some of the important criteria for selection of PCR systems include consistent quality of data, sensitivity, services and support, high-throughput ability, multiplexing capacity, ease of use, and price and brand of instrument.

Needle Free Injection System Market worth 20.17 Billion USD by 2021

The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 Billion by 2021 from USD 9.81 Billion in 2016, at a CAGR of 15.5% during the forecast period. 

Growth in this market is mainly driven by growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, rising demand for biosimilars and vaccination, advantages of drug delivery technology, increasing demand for self-injection devices. On the other hand, high development cost of needle-free injection systems over the conventional needle injection may hinder the growth of this market during the forecast period.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=165815861

The market is dominated by North America, followed by Europe, Asia, and the Rest of the World. While North America is expected to dominate the market in 2016, Europe is expected to grow at the highest CAGR during the forecast period.  The high growth in this market is attributed to the rising demand for biologics, growing prevalence of chronic diseases, technological advancements, mergers and acquisitions by major companies in the market, favorable reimbursement policies, increasing healthcare expenditure and regulatory approvals of new injection system are key factors driving the market growth in Europe

Global Needle Free Injection System Market, By Product 

• Fillable Needle-Free Injectors
• Prefilled Needle-Free Injectors

Global Needle Free Injection System Market, By Technology

• Jet-Based Needle-Free Injectors
• Spring-Based Needle-Free Injectors
• Laser-Powered Needle-Free Injectors
• Vibration-Based Needle-Free Injectors

Global Needle Free Injection System Market, By Usability

• Reusable Needle-Free Injectors
• Disposable Needle-Free Injectors

Global Needle Free Injection System Market, by type of Medication

• Liquid-based needle free injectors
• Powder-based needle free injectors
• Projectile/depot-based needle free injectors

Global Needle Free Injection System Market, by Site of Delivery

• Intra dermal injectors
• Intramuscular injectors
• Subcutaneous injectors

Global Needle Free Injection System Market, by Application

• Vaccine Needle free delivery
• Insulin Needle free delivery
• Pain Management Needle free delivery
• Oncology Needle free delivery
• Others applications

Global Needle Free Injection System Market, by End User

• Hospitals and Clinics
• Homecare Settings
• Research Laboratories
• Pharmaceutical and Biotechnology companies
• Other End Users 

Key players in the needle-free injection system market include  Antares Pharma, Inc. (U.S.), Endo International plc (U.S.), PharmaJet (U.S), Bioject Medical Technologies Inc. (U.S), Medical International Technology, Inc. (U.S), INJEX Pharma AG (Germany), National Medical Products Inc. (U.S.), Valeritas, Inc. (U.S.), European Pharma Group (Netherland), PenJet Corporation (U.S), Crossject SA (France).

There is Increase in Funding for Proteomics and Glycomics Research, Growing R&D Expenditure

Factors such as increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies are the key drivers for the growth of the market. Whereas, the high degree of consolidation is expected to restrict the entry of new players in the market, and thereby hinder its growth.

On the basis of product, the market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to their consumable nature and wide applications in a variety of R&D and drug discovery procedures. The enzymes segment is further divided into glycosidases, glycosyltransferases, neuraminidases, sialyltransferases, and other enzymes.

The global glycomics market is poised to reach USD 1,211.4 Million by 2021 from USD 649.5 Million in 2016, at a CAGR of 13.3%.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=132685525

The key players in the glycomics market include Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).

Glycomics Market, by End User

•Academic Research Institutes
•Pharmaceutical & Biotechnology Companies
•Contract Research Organizations

Glycomics Market, by Application

•Diagnostics•Drug Discovery & Development
•Oncology
•Immunology
•Other Application

The global glycomics market was dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Over the next five years, the growth of the glycobiology market in the Asian region is likely to be centered on China, India, and Japan.